Ophthalmic gene therapy Luxturna wins EU backing

Switzerland-based Novartis (NOVN: VX) has won European approval for the one-time gene therapy Luxturna (voretigene neparvovec). The treatment ...

source https://www.thepharmaletter.com/article/ophthalmic-gene-therapy-luxturna-wins-eu-backing